What is it about?

Anti-hormonal medication is intended to prevent breast cancer recurrence. For half of the women who are recommended to take anti-hormonal medication after the initial treatment for breast cancer has ended, it can be challenging to continue the treatment for five years. The latest findings do not show any improvement in the adherence rate. Findings are based on the National Dutch Cancer Registry and the PHARMO data base.

Featured Image

Why is it important?

Health care provider should know that adherence to anti-hormonal medication might be low. As the literature indicates, the topic is often not discussed, which implies that potential solutions are not explored.


We need to find ways to prepare and educate women about the challenges of anti-hormonal therapy. As health care providers are already busy, a lot of help can be provided using digital technology, so care providers can discuss problems with informed women and focus on the fine-tuning of solutions for individual woman.

Associate professor Ilse Mesters
Maastricht University

Read the Original

This page is a summary of: 5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006–2016), Breast Disease, November 2023, IOS Press,
DOI: 10.3233/bd-230024.
You can read the full text:



The following have contributed to this page